Skip to main content

Advertisement

SpringerLink
Log in

Effect of Diane-35, alone or in combination with orlistat or metformin in Chinese polycystic ovary syndrome patients

  • Gynecologic Endocrinology and Reproductive Medicine
  • Published:
Archives of Gynecology and Obstetrics Aims and scope Submit manuscript

Abstract

Objective

To evaluate the effect of Diane-35, alone or in combination with orlistat or metformin, on androgen and body fat percentage parameters in Chinese overweight and obese polycystic ovary syndrome (PCOS) patients with insulin resistance.

Methods

A total of 240 PCOS women were randomly allocated to receive Diane-35 alone (D group), Diane-35 plus orlistat (DO group), Diane-35 plus metformin (DM group), or Diane-35 plus orlistat plus metformin (DOM group). Serum TT, DHEA-S, androstenedione, SHBG, FT, FAI, body fat, and body fat percentage were assessed at baseline and after 12 weeks of treatment.

Results

Significant changes in serum TT, SHBG, and FAI were observed in all treatment groups compared with baseline. DHEA-S and androstenedione significantly decreased in the DO, DM, and DOM groups after treatment. FT only significantly decreased in the DOM group. Body fat and body fat percentage significantly decreased in the DO and DOM groups. Compared with the D group, DHEA-S significantly decreased in the DO, DM, and DOM groups (F = 4.081, p = 0.008); SHBG significantly increased in the DOM group (F = 3.019, p = 0.031); and FAI significantly decreased in the DO group (χ2 = 12.578, p = 0.006). There were significant differences between groups in body fat percentage (χ2 = 23.590, p < 0.001). Side-effects were less with orlistat than metformin.

Conclusions

Diane-35 in combination with orlistat or metformin is more effective in reducing androgen than Diane-35 alone. Orlistat is more effective in reducing body fat percentage than metformin. In addition, orlistat has mild side-effects and is better tolerated compared with metformin.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Goodman NF, Cobin RH, Futerweit W et al (2015) American association of clinical endocrinologists, American college of endocrinology, and androgen excess and PCOS society disease state clinical review: guide to the best practices in the evaluation and treatment of polycystic ovary syndrome—PART 2. Endoc Pract 21:1415–1426

    Article  Google Scholar 

  2. Lizneva D, Suturina L, Walker W et al (2016) Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertil Steril 106:6–15

    Article  PubMed  Google Scholar 

  3. Ali AT (2015) Polycystic ovary syndrome and metabolic syndrome. Ceska Gynekol 80:279–289

    PubMed  Google Scholar 

  4. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group (2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 81:19–25

    Google Scholar 

  5. Royal College of Obstetricians and Gynecologists (2014) Polycystic ovary syndrome, long-term consequences (Green-top Guideline No. 33). https://www.rcog.org.uk/en/guidelines-research-services/guidelines/gtg33/. Accessed 05 Nov 2014

  6. Conway G, Dewailly D, Diamanti-Kandarakis E et al (2014) The polycystic ovary syndrome: a position statement from the European society of endocrinology. Eur J Endocrinol 171:1–29

    Article  Google Scholar 

  7. Buzney E, Sheu J, Buzney E et al (2014) Polycystic ovary syndrome: a review for dermatologists, Part II. Treatment. J Am Acad Dermatol 71:859.e1–859.e15

    Article  Google Scholar 

  8. Ruan X, Kubba A, Aguilar A et al (2017) Use of cyproterone acetate/ethinylestradiol in polycystic ovary syndrome: rationale and practical aspects. Eur J Contracept Reprod Health Care 22:183–190

    Article  CAS  PubMed  Google Scholar 

  9. Williams T, Mortada R, Porter S (2016) Diagnosis and treatment of polycystic ovary syndrome. Am Fam Physician 94:106–113

    PubMed  Google Scholar 

  10. Wang YW, He SJ, Feng X et al (2017) Metformin: a review of its potential indications. Drug Des Devel Ther 11:2421–2429

    Article  PubMed  PubMed Central  Google Scholar 

  11. Ladson G, Dodson WC, Sweet SD et al (2011) The effects of metformin with lifestyle therapy in polycystic ovary syndrome: a randomized double-blind study. Fertil Steril 95:1059–1066

    Article  CAS  PubMed  Google Scholar 

  12. Kumar P, Arora S (2014) Orlistat in polycystic ovarian syndrome reduces weight with improvement in lipid profile and pregnancy rates. J Hum Reprod Sci 7:255–261

    Article  PubMed  PubMed Central  Google Scholar 

  13. Alqahtani S, Qosa H, Primeaux B et al (2015) Orlistat limits cholesterol intestinal absorption by Niemann-pick C1-like 1 (NPC1L1) inhibition. Eur J Pharmacol 762:263–269

    Article  CAS  PubMed  Google Scholar 

  14. Ahn SM, Kim H, Ji E et al (2014) The effect of orlistat on weight reduction in obese and overweight Korean patients. Arch Pharm Res 37:512–519

    Article  CAS  PubMed  Google Scholar 

  15. Wu H, Ruan X, Jin J et al (2015) Metabolic profile of Diane-35 versus Diane-35 plus metformin in Chinese PCOS women under standardized life-style changes. Gynecol Endocrinol 31:548–551

    Article  CAS  PubMed  Google Scholar 

  16. Yang YM, Choi EJ (2015) Efficacy and safety of metformin or oral contraceptives, or both in polycystic ovary syndrome. Ther Cin Risk Manag 11:1345–1353

    CAS  Google Scholar 

  17. Vilmann LS, Thisted E, Baker JL et al (2012) Development of obesity and polycystic ovary syndrome in adolescents. Horm Res Paediatr 78:269–278

    Article  CAS  PubMed  Google Scholar 

  18. Naderpoor N, Shorakae S, Joham A et al (2015) Obesity and polycystic ovary syndrome. Minerva Endocrinol 40:37–51

    CAS  PubMed  Google Scholar 

  19. Baptiste CG, Battista MC, Trottier A et al (2010) Insulin and hyperandrogenism in women with polycystic ovary syndrome. J Steroid Biochem Mol Biol 122:42–52

    Article  CAS  PubMed  Google Scholar 

  20. Tosi F, Bonora E, Moghetti P (2017) Insulin resistance in a large cohort of women with polycystic ovary syndrome: a comparison between euglycaemic-hyperinsulinaemic clamp and surrogate indexes. Hum Reprod 13:1–7

    Google Scholar 

  21. Nestler JE, Powers LP, Matt DW et al (1991) A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab 72:83–89

    Article  CAS  PubMed  Google Scholar 

  22. Feng W, Jia YY, Zhang DY et al (2016) Management of polycystic ovarian syndrome with Diane-35 or Diane-35 plus metformin. Gynecol Endocrinol 32:147–150

    Article  PubMed  Google Scholar 

  23. Panidis D, Tziomalos K, Papadakis E et al (2014) The role of orlistat in combination with lifestyle changes in the management of overweight and obese patients with polycystic ovary syndrome. Clin Endocrinol (Oxf) 80:432–438

    Article  CAS  Google Scholar 

  24. Gallo MF, Lopez LM, Grimes DA et al (2014) Combination contraceptives: effects on weight. Cochrane Database Syst Rev 29:CD003987

    Google Scholar 

  25. Glintborg D, Altinok ML, Mumm H et al (2014) Body composition is improved during 12 months’ treatment with metformin alone or combined with oral contraceptives compared with treatment with oral contraceptives in polycystic ovary syndrome. J Clin Endocrinol Metab 99:2584–2591

    Article  CAS  PubMed  Google Scholar 

  26. de Bastos M, Stegeman BH, Rosendaal FR et al (2014) Combined oral contraceptives: venous thrombosis. Cochrane Database Syst Rev 3:CD010813

    Google Scholar 

  27. Sandset PM (2014) Combined oral contraceptives increase risk of venous thrombosis according to oestrogen dose and type of progestogen. Evid Based Med 19:194

    Article  PubMed  Google Scholar 

  28. Okoroh EM, Hooper C, Atrash HK et al (2012) Is polycystic ovary syndrome anther risk factor for venous thromboembolism? United States 2003–2008. Am J Obstet Gynecol 207(377):e1–e8

    Google Scholar 

  29. Bird ST, Hartzema AG, Brophy JM et al (2013) Risk of venous thromboembolism in women with polycystic ovary syndrome: a population-based matched cohort analysis. CMAJ 185:E115–E120

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

The authors especially thank Prof. Xingming Li for his assistance in statistical analysis of the data.

Author information

Authors and Affiliations

  1. Department of Gynecological Endocrinology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing, 100026, China

    Xiangyan Ruan, Jinghua Song, Muqing Gu, Lijuan Wang, Husheng Wang & Alfred O. Mueck

  2. Department of Women’s Health, University Hospitals of Tuebingen, Tuebingen, Germany

    Xiangyan Ruan & Alfred O. Mueck

  3. Department of Obstetrics and Gynecology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China

    Jinghua Song

Authors
  1. Xiangyan Ruan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jinghua Song
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Muqing Gu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lijuan Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Husheng Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Alfred O. Mueck
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

XR: Project development, manuscript writing; JS: data collection, data analysis; MG: data collection; LW: data collection; HW: data collection; AOM: manuscript editing

Corresponding author

Correspondence to Xiangyan Ruan.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Funding

This study was supported by Capital Characteristic Clinic Project of China (Z161100000516143); Beijing Capital Foundation for Medical Science Development and Research (2016-2-2113); Clinical Technique Innovation Project of Beijing Municipal Administration of Hospitals (XMLX201710); Beijing Municipality Health Technology High-level Talent (2014-2-016); Foreign technical and administrative talent introduction project in 2017, State Administration of Foreign Experts Affairs, the P. R. of China (20171100004).

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ruan, X., Song, J., Gu, M. et al. Effect of Diane-35, alone or in combination with orlistat or metformin in Chinese polycystic ovary syndrome patients. Arch Gynecol Obstet 297, 1557–1563 (2018). https://doi.org/10.1007/s00404-018-4762-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00404-018-4762-0

Keywords

Search

Navigation